#antiretrovirals

AVR treatment halts brain damage and reduces damage.

Research found that healthcare providers could do better at preventing drug interactions.

Gene editing in monkeys creates SHIV-resistant immune cells.

Whites have a higher rate of successful HIV treatment.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.

This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

The risk for cervical cancer is lower for women living with HIV on treatment.

A star-shaped drug capsule could permit weekly dosing of HIV meds.

A recent small study compared objective and subjective fatigue among those with and without HIV who were age 50 and older.

The researchers studied a new compound that blocked a key viral protein that prompts infected cells to produce more virus.

Juluca is a single-tablet regimen for HIV.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.